These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16188993)

  • 1. Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme.
    Simsek E; Mehta A; Zhou T; Dwek RA; Block T
    J Virol; 2005 Oct; 79(20):12914-20. PubMed ID: 16188993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus MHBs antigen is selectively sensitive to glucosidase-mediated processing in the endoplasmic reticulum.
    Lu X; Lu Y; Geschwindt R; Dwek RA; Block TM
    DNA Cell Biol; 2001 Oct; 20(10):647-56. PubMed ID: 11749723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP1B3 Restricts Hepatitis B Virus Replication Via Reducing the Expression of the Envelope Proteins.
    Zhang J; Zheng T; Zhou X; Wang H; Li Z; Huan C; Zheng B; Zhang W
    Virol Sin; 2021 Aug; 36(4):678-691. PubMed ID: 33534085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.
    Norton PA; Menne S; Sinnathamby G; Betesh L; Cote PJ; Philip R; Mehta AS; Tennant BC; Block TM
    Hepatology; 2010 Oct; 52(4):1242-50. PubMed ID: 20658465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors.
    Fujita K; Omura S; Silver J
    J Gen Virol; 1997 Mar; 78 ( Pt 3)():619-25. PubMed ID: 9049413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity.
    Lazar C; Durantel D; Macovei A; Zitzmann N; Zoulim F; Dwek RA; Branza-Nichita N
    Antiviral Res; 2007 Oct; 76(1):30-7. PubMed ID: 17548120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligosaccharide trimming plays a role in the endoplasmic reticulum-associated degradation of tyrosinase.
    Wang Y; Androlewicz MJ
    Biochem Biophys Res Commun; 2000 Apr; 271(1):22-7. PubMed ID: 10777675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B Virus Middle Protein Enhances IL-6 Production via p38 MAPK/NF-κB Pathways in an ER Stress-Dependent Manner.
    Li YX; Ren YL; Fu HJ; Zou L; Yang Y; Chen Z
    PLoS One; 2016; 11(7):e0159089. PubMed ID: 27434097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins.
    Simsek E; Lu X; Ouzounov S; Block TM; Mehta AS
    Antivir Chem Chemother; 2006; 17(5):259-67. PubMed ID: 17176630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biogenesis of the hepatitis B viral middle (M) surface protein in a human hepatoma cell line: demonstration of an alternative secretion pathway.
    Sheu SY; Lo SJ
    J Gen Virol; 1994 Nov; 75 ( Pt 11)():3031-9. PubMed ID: 7964612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tocotrienol on the intracellular translocation and degradation of apolipoprotein B: possible involvement of a proteasome independent pathway.
    Wang Q; Theriault A; Gapor A; Adeli K
    Biochem Biophys Res Commun; 1998 May; 246(3):640-3. PubMed ID: 9618265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus.
    Chua PK; Wang RY; Lin MH; Masuda T; Suk FM; Shih C
    J Virol; 2005 Nov; 79(21):13483-96. PubMed ID: 16227269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited.
    Lu X; Mehta A; Dadmarz M; Dwek R; Blumberg BS; Block TM
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2380-5. PubMed ID: 9122203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucosamine-induced endoplasmic reticulum stress promotes ApoB100 degradation: evidence for Grp78-mediated targeting to proteasomal degradation.
    Qiu W; Kohen-Avramoglu R; Mhapsekar S; Tsai J; Austin RC; Adeli K
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):571-7. PubMed ID: 15618547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannosidase action, independent of glucose trimming, is essential for proteasome-mediated degradation of unassembled glycosylated Ig light chains.
    Chillarón J; Adán C; Haas IG
    Biol Chem; 2000 Dec; 381(12):1155-64. PubMed ID: 11209750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the relations between hepatitis B virus large surface protein (LHBs) and HBV YMDD mutation].
    Wang LJ; Sun Y; Fu HP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Feb; 24(1):48-9. PubMed ID: 20848850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice.
    Geissler M; Schirmbeck R; Reimann J; Blum HE; Wands JR
    Hepatology; 1998 Jul; 28(1):202-10. PubMed ID: 9657113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays for glucosidase inhibitors with potential antiviral activities: secreted alkaline phosphatase as a surrogate marker.
    Norton PA; Conyers B; Gong Q; Steel LF; Block TM; Mehta AS
    J Virol Methods; 2005 Mar; 124(1-2):167-72. PubMed ID: 15664065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact on tyrosinase expression and export from endoplasmic reticulum by inhibition of 26S proteasome].
    Xu W; Lin FQ; Liu JF; Fu LF; Hong WS; Zhou MN; Xu AE; Guan CP
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):123-7. PubMed ID: 23648349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.